Get started
Author

Daisy Mugo

Observed names: D Mugo, D. Mugo, Mugo, Daisy, Mugo, daisy
Observed institutions: Kenya Medical Research Institute, University of Oxford, London School of Hygiene & Tropical Medicine, KEMRI-Wellcome Trust Research Programme, University College London, Wellcome Trust
ORCID: 0000-0003-3128-2461
Observed ORCID: 0000-0003-3128-2461
OpenAlex ID: A5040183990
Seroprevalence of anti–SARS-CoV-2 IgG antibodies in Kenyan blood donors
2020 · Sophie Uyoga, Ifedayo M.O. Adetifa, et al. · Science · 308
The Prevalence and Risk Factors for Pneumococcal Colonization of the Nasopharynx among Children in Kilifi District, Kenya
2012 · Osman Abdullahi, Angela Karani, et al. · PLoS ONE · 126
PDF
Rates of Acquisition and Clearance of Pneumococcal Serotypes in the Nasopharynges of Children in Kilifi District, Kenya
2012 · Osman Abdullahi, Angela Karani, et al. · The Journal of Infectious Diseases · 105
PDF
COVID-19 transmission dynamics underlying epidemic waves in Kenya
2021 · Samuel P. C. Brand, John Ojal, et al. · Science · 85
Rates of Acquisition of Pneumococcal Colonization and Transmission Probabilities, by Serotype, Among Newborn Infants in Kilifi District, Kenya
2012 · C. C. Tigoi, H. Gatakaa, et al. · Clinical Infectious Diseases · 64
PDF
Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya
2021 · Ifedayo M. O. Adetifa, Sophie Uyoga, et al. · Nature Communications · 60
PDF
Standardization of Laboratory Methods for the PERCH Study
2017 · Amanda J. Driscoll, Ruth A. Karron, et al. · Clinical Infectious Diseases · 51
PDF
Performance of the MGIT TBc Identification Test and Meta-Analysis of MPT64 Assays for Identification of the Mycobacterium tuberculosis Complex in Liquid Culture
2011 · Andrew J. Brent, Daisy Mugo, et al. · Journal of Clinical Microbiology · 51
Prevalence of SARS-CoV-2 Antibodies From a National Serosurveillance of Kenyan Blood Donors, January-March 2021
2021 · Sophie Uyoga, Ifedayo M.O. Adetifa, et al. · JAMA · 45
PDF
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya
2021 · Anthony O Etyang, Ruth Lucinde, et al. · Clinical Infectious Diseases · 42
PDF
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
2023 · Daniel Jenkin, Daniel Wright, et al. · The Lancet Infectious Diseases · 38
Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21
2022 · R. Lucinde, D. Mugo, et al. · PLoS ONE · 30
SARS-CoV-2 seroprevalence in three Kenyan health and demographic surveillance sites, December 2020-May 2021
2022 · Anthony O. Etyang, Ifedayo Adetifa, et al. · PLOS Global Public Health · 28
Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immunoglobulin G Antibody Seroprevalence Among Truck Drivers and Assistants in Kenya
2021 · E Wangeci Kagucia, John N Gitonga, et al. · Open Forum Infectious Diseases · 28
PDF
Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels
2021 · C. Bottomley, M. Otiende, et al. · Nature Communications · 27
PDF
Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations
2021 · James Nyagwange, Bernadette Kutima, et al. · Journal of Clinical Virology · 22
PDF
SARS‐CoV‐2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February–December 2022
2023 · E. Wangeci Kagucia, Abdhala K. Ziraba, et al. · Influenza and Other Respiratory Viruses · 21
PDF
Bacteriological diagnosis of childhood TB: a prospective observational study
2017 · Andrew J. Brent, Daisy Mugo, et al. · Scientific Reports · 19
PDF
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial
2023 · Derick Kimathi, Aitana Juan-Giner, et al. · The Lancet Infectious Diseases · 18
PDF
Low-Dose Yellow Fever Vaccine in Adults in Africa
2025 · Derick Kimathi, Aitana Juan-Giner, et al. · New England Journal of Medicine · 16
PDF
Epidemiology of COVID-19 infections on routine polymerase chain reaction (PCR) and serology testing in Coastal Kenya
2022 · James Nyagwange, Leonard Ndwiga, et al. · Wellcome Open Research · 16
PDF
Fractional Doses of Pneumococcal Conjugate Vaccine — A Noninferiority Trial
2024 · Katherine E. Gallagher, Ruth Lucinde, et al. · New England Journal of Medicine · 14
PDF
Pooled testing conserves SARS-CoV-2 laboratory resources and improves test turn-around time: experience on the Kenyan Coast
2020 · Charles N. Agoti, Martin Mutunga, et al. · Wellcome Open Research · 13
An optimisation of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams
2020 · Khadija Said Mohammed, Zaydah R. de Laurent, et al. · Wellcome Open Research · 13
PDF
Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, JN.1.4, and KP.3.1.1 using samples from two health demographic surveillance systems in Kenya
2024 · Doreen Lugano, Bernadette Kutima, et al. · BMC Infectious Diseases · 12
PDF
Works count: 52
Citation count: 1,303
H-index: 18
I10-index: 27
Year
Topic
Type